跳转至内容
Merck
CN
  • Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin.

Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin.

Transplant infectious disease : an official journal of the Transplantation Society (2009-01-16)
P Lichtenberger, I Rosa-Cunha, M Morris, S Nishida, E Akpinar, J Gaitan, A Tzakis, S Doblecki-Lewis
摘要

Severe strongyloidiasis, including hyperinfection and dissemination, is a recognized complication of solid organ transplantation. However, the development of strongyloidiasis in a liver transplant recipient has not been previously described. We present a case of severe strongyloidiasis occurring in a patient 4 months after liver transplantation and 1 month after receiving treatment for acute rejection. We assess the management challenges in this patient who remained symptomatic despite oral treatment with ivermectin and albendazole and eventual successful treatment with parenteral ivermectin. We review the published experience with alternative methods of ivermectin administration. We also investigate the possible source of infection, as the patient was not from an endemic area.

材料
产品编号
品牌
产品描述

伊维菌素, European Pharmacopoeia (EP) Reference Standard